Science
First Werner helicase drug shows durable tumour responses in Phase 1
MD Anderson-led Nature Medicine data validate a synthetic-lethal path for MSI cancers that shrug off immunotherapy.
Published: September 29, 2026 · 1 min read
A first-in-class drug that shuts down the DNA-repair enzyme Werner helicase produced durable partial responses and a high disease-control rate in patients with microsatellite-instability or mismatch-repair-deficient solid tumours, according to Phase 1 results published Tuesday in Nature Medicine from a trial led by researchers at The University of Texas MD Anderson Cancer Center.
VVD-133214 (formerly RO7589831), developed with Vividion Therapeutics after early Roche backing, is the first covalent Werner helicase inhibitor in the clinic. Among 66 efficacy-evaluable patients — a heavily pretreated group, 95.5 per cent of whom had already received immune checkpoint therapy — seven had radiologic partial responses across multiple cancer types, and the disease-control rate was 74.2 per cent. Median duration of response was 10.2 months; five of seven responders were still responding at data cutoff. Safety in 88 patients was mostly grade 1–2 nausea, vomiting and diarrhea; three patients discontinued for adverse events. Lead investigator Timothy Yap said the data validate Werner helicase as an actionable target for patients with few options after immunotherapy fails.
Roughly 40 to 70 per cent of patients with MSI/dMMR solid tumours never respond to checkpoint inhibitors or later relapses. Follow-on trials are already open: a Phase 1b pairing the drug with bevacizumab in post-immunotherapy metastatic colorectal cancer, and a Phase 2 combining it with pembrolizumab in treatment-naïve metastatic colorectal disease. Canadian oncology centres that already sequence MSI status for immunotherapy eligibility will watch whether WRN inhibition becomes the next synthetic-lethal standard beside PARP inhibitors — a rare new lever when checkpoint drugs stall.
Newsletter
News. Context. What matters.
One essential briefing, written for people who would rather understand the story than scroll it.
Unsubscribe anytime. We don’t sell addresses.
Recommended
Science
From the space station, Joshua Kutryk describes the northern lights and relearning daily life as Canadian health studies get under way
In his first news conference from orbit, the Canadian Space Agency astronaut said he has lost five pounds and is taking part in Canadian-led research on astronaut health; a SpaceX cargo ship launched Tuesday with more experiments.
Science
About one in six Canadian doctors reports a disability at least some of the time, CMAJ census study finds
An Ottawa Hospital-led analysis of 2021 long-form census data found mental health and vision were the most commonly reported disabilities, and its authors call for more accessible medical workplaces.
Science
More than half of species assessed at risk since 2017 are overdue for federal listing decisions, SFU-led study finds
Only 17 of 288 COSEWIC-assessed species reached Cabinet on time; none of the marine mammals or marine fish assessed in the period had been forwarded by January 2025, researchers report in FACETS.